Neuroendocrine tumor of gallbladder with liver and retroperitoneal metastases and a good response to the chemotherapeutical treatment

Chiorean, Liliana; Bartoș, Adrian; Pelau, D.; Iancu, Dana; Ciuleanu, Tudor-Eliade; Buiga, Rareș; Oancea, Irinel; Mangrau, Angelica; Iancu, Cornel; Badea, Radu

doi:10.1007/s10396-014-0585-1

Cited by 13 publications

(14 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A study by the Memorial Sloan Kettering Cancer Center demonstrated that the median survival time of 13 patients with GB-NEC was only slightly shorter compared with that of 435 patients with gallbladder cancer (9.8 months vs. 10.3 months, respectively) (14). Chiorean et al (11) demonstrated that GB-NEC 1-, 2-and 3-year survival rates were lower compared with those of other types of gallbladder cancer (20 vs. 38%; 10 vs. 31%; 0 vs. 30.1%, respectively) during the same period.…”

Section: Prognosismentioning

confidence: 99%

“…To identify the root cause of the GB-NEN, a thorough examination and understanding of the cellular nature of the disease is important. In the process of examination, minimal neuroendocrine cells can be found on the gallbladder mucosa, if any exist in this space (11)(12)(13). Further GB-NEN etiological identifiers may be as follows: i) The undifferentiated gallbladder stem cells separate into neuroendocrine cells.…”

Section: Causesmentioning

confidence: 99%

“…For rapidly growing tumors, chemotherapy response rates range from 20-60% worldwide (52). Based on the differing degrees of tumor differentiation, the most commonly used chemotherapy drugs include streptozotocin, 5-fluorouracil, adriamycin, cisplatin and etoposide (11). Due to the clinical incidence of GB-NEN being low, there are few associated studies available, which results in the lack of a unified standard chemotherapy program.…”

Section: Treatment Optionsmentioning

confidence: 99%

“…Available studies have demonstrated that oxaliplatin plus gemcitabine is the most effective chemotherapy regimen for gallbladder cancer at present; however, cholecystic NEC has a poor response to this treatment. Therefore, chemotherapy drugs advocated for gastrointestinal and cholecystic NEC include etoposidem, cisplatin and Adriamycin (11). Associated case reports demonstrated that the post-operative use of gemcitabine, docetaxel, or cisplatin combined with cisplatin, sunitinib and docetaxel, respectively, resulted in a longer survival time in patients with GB-NENs (53,54).…”

Section: Treatment Optionsmentioning

confidence: 99%

See 3 more Smart Citations

Neuroendocrine tumors of the gallbladder (Review)

et al. 2020

View full text Add to dashboard Cite

A gallbladder neuroendocrine neoplasm (GB-NEN) is a unique heterogeneous neoplasm, originating from neuroendocrine cells and able to secrete peptides as its neurotransmitter. Among all the neuroendocrine tumors (NETs), the GB-NEN prevalence is 0.5%, which accounts for ~2.1% of all gallbladder tumors. The current study aimed to present an up-to-date review of the clinical features, diagnosis and treatment of NETs of the gallbladder. A systematic literature search was performed in order to identify all relevant studies published. Thus far, the etiology and pathogenesis of GB-NEN remains unclear. Moreover, an ambiguous clinical manifestation exists as observed during laboratory examinations. As GB-NEN is a rare gallbladder lesion and is seldom seen in clinical practice, there is a limited availability of review reports, and it is therefore often considered only as a case study. It is difficult to distinguish GB-NEN from other gallbladder diseases using imaging diagnostic techniques. Although chemotherapy treatment provides prolonged progression-free survival, surgery is considered the best option. Thus, to overcome the inherent risks or shortfalls of traditional surgery; early detection, diagnosis and treatment of GB-NEN are required to improve patient longevity.

show abstract

Section: Prognosismentioning

confidence: 99%

Section: Causesmentioning

confidence: 99%

Section: Treatment Optionsmentioning

confidence: 99%

Section: Treatment Optionsmentioning

confidence: 99%

See 2 more Smart Citations

Neuroendocrine tumors of the gallbladder (Review)

et al. 2020

View full text Add to dashboard Cite

show abstract

“…The presence of liver metastasis is a distinguishing feature of malignant NETs and is an important prognostic factor in patient survival [11]. Surgery has a primary role in the management of neuroendocrine liver metastasis (NELM) and its impact is well appreciated in both curative and palliative settings [12]. The role of chemotherapy and radiotherapy in the management of GB NETs and particularly those developing NELM is equivocal [3]; therefore, surgery remains the best treatment option if complete surgical resection (R0) of NELM can be achieved.…”

Section: Discussionmentioning

confidence: 99%

Repeat liver resection for pure large cell neuroendocrine carcinoma of the gallbladder: a favorable outcome

et al. 2019

View full text Add to dashboard Cite

Background The pure large cell type is a rare variant of primary neuroendocrine carcinoma of the gallbladder. Few reports have mentioned extended survival. Although a multimodal treatment has been described in the treatment of such rare disease, redo liver resection has not yet been mentioned. Case report A 67-year-old lady was found to have poorly differentiated, high grade, pure large cell neuroendocrine tumor of the gallbladder after cholecystectomy for gallstones. After the diagnosis, staging workup showed a lesion in segment IVB/V of the liver, and chromogranin was elevated (982 mcg/L). The patient underwent central inferior hepatectomy and wedge excision of a lesion in segment III (discovered intra-operatively), with hilar lymphadenectomy. Three months after the first liver resection, she developed a new liver lesion II/III and underwent left lateral liver resection. The patient remained disease-free for 4 months following the second liver resection but then developed recurrent liver disease and was started on chemotherapy. Further progression led to multi-organ failure and death at 26 months from initial diagnosis. Conclusion This is the first reported repeat liver resection in such a rare disease that has led to extended overall survival. We suggest that a group of selected patients with this rare malignancy, and liver-limited disease, may benefit from repeated liver resection.

show abstract